|
|
Article: genOway acquires exclusive license for Flex technology developed by Professor Pierre Chambon and Dr. Norbert Ghyselinck at the IGBMC.
- Article from:
- Blood Weekly
- Article date:
- November 19, 2009
CopyrightCOPYRIGHT 2009 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
genOway (ALTERNEXT-NYSE EURONEXT: ALGEN ; ISIN : FR0004053510), the biotechnology company dedicated to the development of genetically modified animal models, reports the signing of an exclusive license for Flex technology, developed at the Institute of Genetics and Molecular and Cellular Biology (IGBMC, Strasbourg), directed by Professor Pierre Chambon. The financial terms of the agreement were not disclosed.
This technology, combining a recombinase system with genetic modification, is the only one allowing the creation of inducible mutations. Indeed, the Flex technology enables the desired mutation to be induced in the selected target tissue at a precise moment ...